Volume 65, Issue 6, Pages (June 2014)

Slides:

Advertisements

Similar presentations

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

Advertisements

Volume 67, Issue 1, Pages (January 2015)

The PSA Era is not Over for Prostate Cancer

TBCRC (the translational breast cancer research consortium) 005 Prospective study

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Testosterone Therapy in Men With Prostate Cancer

Volume 70, Issue 6, Pages (December 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 70, Issue 6, Pages (December 2016)

Volume 67, Issue 1, Pages (January 2015)

Volume 68, Issue 4, Pages (October 2015)

Volume 73, Issue 6, Pages (June 2018)

Volume 53, Issue 5, Pages (May 2008)

Volume 52, Issue 3, Pages (September 2007)

Volume 69, Issue 5, Pages (May 2016)

Volume 51, Issue 4, Pages (April 2007)

Volume 65, Issue 6, Pages (June 2014)

Volume 71, Issue 2, Pages (February 2017)

Epigenetics in Prostate Cancer: Biologic and Clinical Relevance

Volume 67, Issue 1, Pages (January 2015)

Prostate Cancer Epidemic in Sight?

Volume 61, Issue 4, Pages (April 2012)

Volume 56, Issue 2, Pages (August 2009)

Volume 72, Issue 5, Pages (November 2017)

Volume 68, Issue 4, Pages (October 2015)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate.

Volume 65, Issue 1, Pages (January 2014)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Prostate Cancer Detection: A View of the Future

Volume 70, Issue 5, Pages (November 2016)

Volume 67, Issue 3, Pages (March 2015)

Shaheen Alanee, Kasmintan Schrader, Kenneth Offit European Urology

Volume 66, Issue 6, Pages (December 2014)

Luis Martínez-Piñeiro European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al

Volume 70, Issue 2, Pages (August 2016)

Mark A. Rubin, Gabriele Girelli, Francesca Demichelis European Urology

Volume 66, Issue 2, Pages (August 2014)

Volume 63, Issue 3, Pages (March 2013)

Volume 62, Issue 4, Pages (October 2012)

Volume 71, Issue 1, Pages (January 2017)

Volume 67, Issue 1, Pages 7-10 (January 2015)

Volume 74, Issue 2, Pages (August 2018)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 73, Issue 1, Pages 4-8 (January 2018)

Volume 53, Issue 1, Pages (January 2008)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 71, Issue 2, Pages (February 2017)

Volume 50, Issue 5, Pages (November 2006)

Re: Christine McKillop

Risk Factors for the Development of Bone Metastases in Prostate Cancer

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 52, Issue 6, Pages (December 2007)

Volume 71, Issue 6, Pages (June 2017)

Volume 71, Issue 5, Pages (May 2017)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 70, Issue 6, Pages (December 2016)

European Urology is “Your” Journal

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

European Urology Oncology

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer Adam Sharp,

Presentation transcript:

Volume 65, Issue 6, Pages 1191-1197 (June 2014) Analytic and Clinical Validation of a Prostate Cancer–Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival Daniel C. Danila, Aseem Anand, Nikolaus Schultz, Glenn Heller, Mingliang Wan, Clifford C. Sung, Charles Dai, Raya Khanin, Martin Fleisher, Hans Lilja, Howard I. Scher European Urology Volume 65, Issue 6, Pages 1191-1197 (June 2014) DOI: 10.1016/j.eururo.2013.07.006 Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 1 Selection of panel of prostate-specific genes highly expressed in prostate tissue and not expressed in peripheral blood mononuclear cells (PBMCs). The Tissue-specific Gene Expression and Regulation (TiGER) database [14], the Prostate Cancer Genomic Project (PCGP) database [15], and the Novartis Gene Expression database [16] (using BioGPS [17]) were queried for genes expressed in prostate tissue but not expressed in PBMCs or in more than two tissues other than prostate. PBMCs=peripheral blood mononuclear cells; RT-PCR=reverse transcription polymerase chain reaction. European Urology 2014 65, 1191-1197DOI: (10.1016/j.eururo.2013.07.006) Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 2 Prognostic value of detection of prostate-specific transcripts and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer. Kaplan-Meier estimate of survival, calculated from time of blood draw and based on (A) detection of two or more prostate-specific transcripts and (B) baseline CTC counts. European Urology 2014 65, 1191-1197DOI: (10.1016/j.eururo.2013.07.006) Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 3 Prognostic value of detection based on the combination of prostate-specific transcripts and circulating tumor cell enumeration in men with metastatic castration-resistant prostate cancer. The Kaplan-Meier estimate of survival, calculated from time of blood draw, based on whether zero, one, or two unfavorable risk factors were present. European Urology 2014 65, 1191-1197DOI: (10.1016/j.eururo.2013.07.006) Copyright © 2013 European Association of Urology Terms and Conditions